Collateral Sensitivity Networks in ALK-positive Lung Cancer Reveals Dynamic Nature of Drug Resistance
Year: 2016
Type: article
Abstract: H3122 ALK-positive NSCLC cell line evolved, over 16 weeks, to resistance for: 4 ALK inhibitors (ceritinib, alectinib, lorlatinib, crizotinib), 3 HSP-90 inhibitors (ganetespib, IPI504, AUY922), paclitaxel, pemetrexed, and etoposide; collateral sensitivities analyzed.
Source: Figshare
Authors: Dhawan, Andrew, Nichol, Daniel, VanderVelde, Robert, Kinose, Fumi, Haura, Eric, Marusyk, Andriy, G. Scott, Jacob
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6902139761